Demethylation of the  MIR145  promoter suppresses migration and invasion in breast cancer

Shui-Yi Liu; Xiao-Yi Li; Wei-Qun Chen; Hui Hu; Bo Luo; Yu-Xiang Shi; Tang-Wei Wu; Yong Li; Qing-Zhi Kong; Hong-Da Lu; Zhong-Xin Lu

doi:10.18632/oncotarget.18686

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Demethylation of the MIR145 promoter suppresses migration and invasion in breast cancer

Shui-Yi Liu, Xiao-Yi Li, Wei-Qun Chen, Hui Hu, Bo Luo, Yu-Xiang Shi, Tang-Wei Wu, Yong Li, Qing-Zhi Kong, Hong-Da Lu and Zhong-Xin Lu _

PDF | HTML | How to cite

Oncotarget. 2017; 8:61731-61741. https://doi.org/10.18632/oncotarget.18686

Metrics: PDF 1253 views | HTML 2377 views | ?

Abstract

Shui-Yi Liu1,2,*, Xiao-Yi Li1,*, Wei-Qun Chen1,2,3,*, Hui Hu1, Bo Luo6, Yu-Xiang Shi6, Tang-Wei Wu1, Yong Li1,7, Qing-Zhi Kong2,3,4,5, Hong-Da Lu2,3,4,5 and Zhong-Xin Lu1,2,3,4

1Department of Medical Laboratory, Central Hospital of Wuhan, Wuhan 430014, China

2Cancer Research Institute of Wuhan, Wuhan 430014, China

3Department of Central Laboratory, Central Hospital of Wuhan, Wuhan 430014, China

4Key Laboratory for Molecular Diagnosis of Hubei Province, Central Hospital of Wuhan, Wuhan 430014, China

5Department of Oncology, Central Hospital of Wuhan, Wuhan 430014, China

6Department of Pathology, Central Hospital of Wuhan, Wuhan 430014, China

7Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA

*These authors have contributed equally to this work

Correspondence to:

Zhong-Xin Lu, email: [email protected]

Hong-Da Lu, email: [email protected]

Keywords: miR-145, methylation, breast cancer, ANGPT2, migration and invasion

Received: November 04, 2016 Accepted: May 12, 2017 Published: June 27, 2017

ABSTRACT

miR-145 has been implicated in the progression of breast cancer. Here, we report that its expression is decreased in breast cancer specimens and cell lines and that this low level of expression is associated with DNA methylation of its gene, MIR145. Methylation of MIR145 has previously been correlated with cell migration and invasion, both in vivo and in vitro. We found that demethylation of MIR145 reactivates miR-145 and contributes to the anti-cancer properties of 5-aza-2′-deoxyazacytidine (5-AzaC). Therefore, miR-145 is a potentially valuable biomarker for breast cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18686

Publication Alerts

Research Papers:

Demethylation of the MIR145 promoter suppresses migration and invasion in breast cancer

Abstract